Elsevier

Biochimie

Volume 123, April 2016, Pages 110-116
Biochimie

Research paper
A novel antimicrobial peptide derived from membrane-proximal external region of human immunodeficiency virus type 1

https://doi.org/10.1016/j.biochi.2016.02.006Get rights and content

Highlights

  • Novel peptide AP16-A from membrane-proximal external region of HIV-1 is described.

  • AP16-A shows antimicrobial activities against Gram-negative and -positive bacteria.

  • AP16-A is safe in eukaryocytic cells.

  • AP16-A kills Gram-negative bacteria and -positive bacteria by different mechanisms.

Abstract

With increasing microbial drug resistance worldwide, antimicrobial peptides (AMPs) are considered promising alternatives to addressing this problem. In this study, a series of synthetic peptides were designed based on the membrane-disrupting properties of the membrane-proximal external region (MPER) of human immunodeficiency virus type 1 (HIV-1) envelope protein. The peptide AP16-A was found to exhibit the most effective antimicrobial activities against both Gram-negative and Gram-positive bacteria. The minimal bactericidal concentration (MBC) of AP16-A ranged from 2 μg/ml to 16 μg/ml. AP16-A had no detectable cytotoxicity in various tissue cultures and a mouse model. Furthermore, results of confocal fluorescence microscopy and the SYTOX Green uptake assay indicated that AP16-A killed Gram-negative bacteria by the combined effects of relatively slow membrane permeabilization and interaction with an intracellular target, while it killed Gram-positive bacteria by a fast membrane permeabilization process, which achieved relatively more rapid bacterial killing kinetics. The results of this study support the potential use of AP16-A as an AMP.

Introduction

The accelerated emergence of drug-resistant bacterial strains caused by the extensive use of traditional antibiotics is a current major threat [1], [2]. Therefore, the development of a more effective treatment to overcome the problem of drug resistance is urgently needed. Antimicrobial peptides (AMPs) can provide a possible alternative to traditional drugs with a new mode of action and remarkable therapeutic effects [3], [4]. Generally, naturally occurring AMPs contain 12–50 amino acids in length, with an overall positive charge and an amphipathic structure. Most AMPs can directly bind to the bacterial membrane and kill the organism by accessing intracellular targets through membrane permeabilization [5], [6], [7], [8]. The net positive charge facilitates the interaction between AMPs and negatively charged microbial surfaces, with the amphipathic secondary structure allowing AMPs to incorporate into microbial membranes [9]. To date, more than 1000 AMPs have been identified in various species, including plants, insects, fish, frogs and mammals [10]. However, most natural AMPs are large, have low potency and are toxic to host cells [11]. Considering these complications, different synthetic AMPs, as well as corresponding mimics, have been the focus of considerable interest in studies aimed at increasing the effectiveness of AMPs [12], [13]. Short designer AMPs that are less likely to induce resistance and show low toxicity to host cells and tissues have the potential to be the most effective candidates [4].

The essential process of HIV-1 entry into a cell is the fusion of the viral and target cell membranes. This crucial step is mediated by the HIV-1 envelope protein [14]. The membrane-proximal external region (MPER, Ac-665WASLWNWFNITNW LWYIK683-NH2), a highly conserved domain of the HIV-1 gp41 ectodomain, plays a critical role in viral envelope glycoprotein mediated-fusion and infectivity [15], [16]. In addition, the epitopes of well-characterized neutralizing antibodies 2F5, Z13 and 4E10 overlap this conserved region. Previous reports have shown that the MPER, with an unusually high percentage of tryptophan (Trp) residues, likely contributes to the membrane-disrupting properties [15]. Indolicidin, an analog of MPER, is also capable of disrupting membranes and has an unusually high number of Trps as well. Indolicidin is 13 amino acids (ILPWKWPWWPWRR) in length and is a naturally occurring AMP isolated from bovine neutrophils [17]. However, a high Trp content in AMPs is associated with high hemolysis, making indolicidin unsuitable for use as an antimicrobial agent [18]. Based on the membrane-disrupting properties of the MPER, we hypothesized that synthetic peptides derived from this region, such as the 4E10 epitope (Ac-NWFNITNWLWYIK-NH2), may have functional properties similar to those of known AMPs.

Although the sequences of AMPs vary greatly, certain amino acids, such as lysine (Lys) or arginine (Arg), are key components of AMPs [19]. In particular, Lys-rich AMPs exhibit rapid, nonhemolytic, broad-spectrum microbicidal properties [20], [21]. Thus, we aimed to increase this activity by adding Lys to the C-terminus of the 4E10 epitope to generate an AMP with 16 amino acids (AP16: Ac-NWFNITNWLWYIKKKK-NH2). In this study, a series of mutant peptides of AP16 were synthesized, and their antimicrobial activities in vitro against Gram-negative and Gram-positive bacteria were determined. Among them, AP16-A exhibited the highest antimicrobial activity. Potential mechanisms for bactericidal activity were also investigated. By showing low toxicity in eukaryocytes and hemolytic activity, AP16-A has the potential for further development and use as an antibiotic.

Section snippets

Bacteria and reagents

Escherichia coli DH5α was purchased from Takara. Bacillus subtilis ATCC 6633 and Staphylococcus epidermidis ATCC 12228 were purchased from the American Type CultureCollection (ATCC). Melittin, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) and lipopolysaccharides (LPS) were purchased from Sigma-Aldrich. Poly-l-lysine and 4,6-diamidino-2-phenylindole (DAPI) were purchased from Roster. SYTOX Green were purchased from KeyGEN BioTECH. N-phenyl-1-napthylamine (NPN) was purchased

Antimicrobial activity

The antimicrobial activities of AP16 and its analogs against E. coli, B. subtilis, and S. epidermidis are shown in Table 2. AP16-A showed high broad-spectrum antimicrobial activity against both Gram-negative and Gram-positive bacteria. The MBCs of AP16-A were lower than 4 μg/ml for B. subtilis and 8 μg/ml for S. epidermidis. E. coli was the least sensitive to AP16-A (MBC = 16 μg/ml). As indicated in Fig. 1, bacterial killing by AP16-A was dose-dependent, further validating its antimicrobial

Discussion

The accelerated emergence of microbial drug resistance poses a significant challenge to public health. The use of AMPs to solve this problem has been the focus of considerable attention [4], [28]. In this study, we designed a novel AMP (AP16-A) based on the membrane-disrupting properties of the 4E10 epitope. In order to allow initial electrostatic interaction with the negatively charged bacterial membrane, we added three Lys to the C-terminus of the 4E10 epitope (because the optimal charge for

Acknowledgments

The current work was supported by the National Natural Science Foundation of China (Grant No. 30700998 and 81200289), Jilin Province Science Foundation for Youths (Grant No. 20130522007JH), and Key Projects of Science and Technology Bureau of Changchun City (Grant No. 14KG052).

References (31)

  • B.M. Peters et al.

    Antimicrobial peptides: primeval molecules or future drugs?

    PLoS Pathog.

    (2010)
  • M.N. Melo et al.

    Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations

    Nat. Rev. Microbiol.

    (2009)
  • M. Zasloff

    Antimicrobial peptides of multicellular organisms

    Nature

    (2002)
  • K.A. Brogden

    Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?

    Nat. Rev. Microbiol.

    (2005)
  • A. Tossi et al.

    Amphipathic, alpha-helical antimicrobial peptides

    Biopolymers

    (2000)
  • Cited by (2)

    • Expression, purification and characterization of a recombinant antimicrobial peptide Hispidalin in Pichia pastoris

      2019, Protein Expression and Purification
      Citation Excerpt :

      All experiments were performed in triplicate. Bactericidal kinetics assay was performed on S. aureus (ATCC 25,923) bacterial strain using a previous method with minor modifications [4,6,9]. Briefly, S. aureus (1 × 103−4 CFU/ml) cells were mixed with rHispidalin (final concentration was 4 × MIC) at a ratio of 1:1 (v:v).

    • Efficient production of a recombinant Venerupis philippinarum defensin (VpDef) in Pichia pastoris and characterization of its antibacterial activity and stability

      2018, Protein Expression and Purification
      Citation Excerpt :

      Antimicrobial peptides (AMPs) generally consist of 10–100 amino acids in length, which are overall positively charged and, in general, have an amphipathic structure. AMPs are important factors in the innate immune system of all living organisms and can directly bind the bacterial membrane directly and kill the invading bacterial pathogens by accessing intracellular targets through membrane permeabilization [1,2]. Different from employed by traditional antibiotics, which kill bacteria by inhibiting a single enzymatic target, AMPs kill bacteria by disrupting nucleic acids and/or functional protein synthesis, protein folding, enzymatic activity, and/or cell wall synthesis of the bacterial hosts [3,4], thus limiting the emergence of multidrug resistant bacterial strains [5].

    View full text